Acute cerebellar syndrome following intermediate-dose cytarabine.
Yeshurun
M
M
Service des maladies du sang, Hopital Saint-Antoine, Paris, France.
Marsot Dupuch
K
K
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001259:Ataxia / Q000139:chemically induced; D001921:Brain / Q000473:pathology*; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004401:Dysarthria / Q000139:chemically induced / Q000175:diagnosis; D020234:Gait Ataxia / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009759:Nystagmus, Pathologic / Q000139:chemically induced* / Q000175:diagnosis; D011241:Prednisone / Q000627:therapeutic use; D013577:Syndrome; D014750:Vincristine / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone